E-ISSN 2231-3206 | ISSN 2320-4672
 

Technical Note 


Difluprednate in ophthalmic practice

Minal M Patel, Deepika Singhal.

Abstract
The present note deals with the use of drug difluprednate in ophthalmic practice. In last few years, prednisolone acetate and betamethasone are strong steroids in use. Currently, the most widely prescribed strong topical corticosteroids in the US is prednisolone acetate 1%. While it controls inflammation effectively, it has not been shown to consistently address postoperative pain and discomfort in a large clinical trial.3 Chances of side effects like ocular hypertension and cataract formation are higher with these steroids. In june 2008 difluprednate ophthalmic emulsion 0.05% was approved by the US Food and Drug Administration (FDA) for the treatment of inflammation and pain associated with ocular surgery. This was the first ophthalmic steroid approved by the FDA since 1973 as it is high in potency and has good safety profile as well as the ability to reduce postoperative pain.

Key words: Ophthalmic practice, Post Operative, Difluprednate


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Minal M Patel
Articles by Deepika Singhal
on Google
on Google Scholar


REFERENCES
1. Schimmer BP, Parker KL. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. In: Hardman JG, Limbird LE, Gilman AG, editors. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 10th Edition. New York: McGraw-Hill; 2001. p.1649-77.
2. Sanders DR, Kraff M. Steroidal and nonsteroidal anti-inflammatory agents. Effects on postsurgical inflammation and blood-aqueous humor barrier breakdown. Arch Ophthalmol 1984;102(10):1453-6. [DOI via Crossref]   
3. Korenfeld M. Difluprednate: changing the landscape of ocular pharmacology. Expert Rev Ophthalmol 2008;3(6):619-25. [DOI via Crossref]   
4. Bikowski J. The position not the presence of the halogen in corticosteroids influences potency and side effects. J Drug Dermatol 2006;5(2):125-30.
5. Yamaguchi M, Yasueda S, Isowaki A, Yamamoto M, Kimura M, Inada K, et al. Formulation of an ophthalmic lipid emulsion containing an anti-inflammatory steroidal drug, difluprednate. Int J Pharm 2005;301(1-2):121-8. [DOI via Crossref]   
6. Fujino A, Ohtu S, Shibata K. Studies on the metabolic fate of difluprednate (DFBA). 3. Metabolism in rats and rabbits after subcutaneous administration. Pharmacometrics 1985;29:713-23.
7. Tajika T, Shirasaki Y, Kimura M. Ocular distribution and metabolism after instillation of difluprednate ophthalmic emulsion in rabbits. The 2007 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). Poster B744, Program 2654. Fort Lauderdale, FL, USA, 6-10 May 2007.
8. Armaly MF. Effect of corticosteroids on intraocular pressure and fluid dynamics. I. The effect of dexamethasone in the normal eye. Arch ophthalmol 1963;70:482-91. [DOI via Crossref]   
9. Armaly MF. Effect of corticosteroids on intraocular pressure and fluid dynamics.II. The effect of dexamethasone in the glaucomatous eye. Arch ophthalmol 1963;70:492-99. [DOI via Crossref]   
10. Senju Pharmaceutical Co.,Ltd.,Osaka, Japan. Phase IIb clinical study of difluprednate 0.05% vs betamethasone 0.1% in the treatment of postoperative inflammation. April 2004. Data on file.
11. Ohji M, Tano Y, Hida T. Efficacy and safety results of a phase III study of difluprednate ophthalmic emulsion 0.05% in postoperative inflammation. The 2007 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). Poster B807, Program 3903. Fort Lauderdale, FL, USA, 6-10 May 2007.
12. Ohno S, Mochizuki M, Usui M. A phase III noninferiority study of difluprednate ophthalmic emulsion 0.05% in the treatment of anterior uveitis. The 2007 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). Poster B808, Program 3904. Fort Lauderdale, FL, USA, 6-10 May 2007.
13. Baudouin C. Allergic reaction to topical eyedrops. Curr Opin Allergy Clin Immunol.2005;5:459-63. [DOI via Crossref]   
14. Price F. Do you welcome BAK? Weighing the toxicity risk. Optometric Management. 2004. Available from: URL: http:/www.optometric.com/article.aspx?articleZ71020
15. Dart J. Corneal toxicity: the epithelium and stroma in iatrogenic and factitious disease. Eye 2003;17:886-92. [DOI via Crossref]   
16. Yee RW. The effect of drop vehicle on the efficacy and side effects of topical glaucoma therapy: a review. Curr Opin Ophthalmol 2007;18:134-9. [DOI via Crossref]   
17. Abelson MB, Washburn S. The downside of tear preservatives. Rev Ophthalmol 2002;9:102-6.
18. Durezol (difluprednate) Ophthalmic Emulsion. Available from: URL: www.rxlist.com/durezol-drug.htm

How to Cite this Article
Pubmed Style

Minal M Patel , Deepika Singhal. Difluprednate in ophthalmic practice. Natl J Physiol Pharm Pharmacol. 2014; 4(1): 92-94. doi:10.5455/njppp.2014.4.280820132


Web Style

Minal M Patel , Deepika Singhal. Difluprednate in ophthalmic practice. https://www.njppp.com/?mno=42457 [Access: June 02, 2022]. doi:10.5455/njppp.2014.4.280820132


AMA (American Medical Association) Style

Minal M Patel , Deepika Singhal. Difluprednate in ophthalmic practice. Natl J Physiol Pharm Pharmacol. 2014; 4(1): 92-94. doi:10.5455/njppp.2014.4.280820132



Vancouver/ICMJE Style

Minal M Patel , Deepika Singhal. Difluprednate in ophthalmic practice. Natl J Physiol Pharm Pharmacol. (2014), [cited June 02, 2022]; 4(1): 92-94. doi:10.5455/njppp.2014.4.280820132



Harvard Style

Minal M Patel , Deepika Singhal (2014) Difluprednate in ophthalmic practice. Natl J Physiol Pharm Pharmacol, 4 (1), 92-94. doi:10.5455/njppp.2014.4.280820132



Turabian Style

Minal M Patel , Deepika Singhal. 2014. Difluprednate in ophthalmic practice. National Journal of Physiology, Pharmacy and Pharmacology, 4 (1), 92-94. doi:10.5455/njppp.2014.4.280820132



Chicago Style

Minal M Patel , Deepika Singhal. "Difluprednate in ophthalmic practice." National Journal of Physiology, Pharmacy and Pharmacology 4 (2014), 92-94. doi:10.5455/njppp.2014.4.280820132



MLA (The Modern Language Association) Style

Minal M Patel , Deepika Singhal. "Difluprednate in ophthalmic practice." National Journal of Physiology, Pharmacy and Pharmacology 4.1 (2014), 92-94. Print. doi:10.5455/njppp.2014.4.280820132



APA (American Psychological Association) Style

Minal M Patel , Deepika Singhal (2014) Difluprednate in ophthalmic practice. National Journal of Physiology, Pharmacy and Pharmacology, 4 (1), 92-94. doi:10.5455/njppp.2014.4.280820132